|Dr. Steven M. Fruchtman||CEO, Pres & Director||865.44k||N/A||1951|
|Mr. Mark Patrick Guerin CPA||Chief Financial Officer||512.19k||N/A||1969|
|Mr. Abraham N. Oler J.D., M.B.A., Esq., CFA||Sr. VP of Corp. Devel. & Gen. Counsel||N/A||N/A||1976|
|Dr. Mark Stephen Gelder||Chief Medical Officer||N/A||N/A||1957|
|Dr. Ramesh Kumar||Advisor||N/A||N/A||1956|
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Onconova Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.